← Back to Search

Behavioural Intervention

Movement Breaks for Type 2 Diabetes

N/A
Recruiting
Led By Jonathan Little, PhD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged 30-75 years old
Have physician-diagnosed type 2 diabetes
Must not have
Taking insulin
Taking beta-blockers
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48-hour ex trial versus the 48-hour con trial
Awards & highlights
No Placebo-Only Group

Summary

"This trial will study how short, light activity breaks affect blood sugar levels in inactive people with type 2 diabetes by using a continuous glucose monitor."

Who is the study for?
This trial is for inactive adults aged 30-75 with type 2 diabetes, a BMI of 18.5-40, stable medication doses for the past 6 months, and an HbA1c of ≤8.5%. Participants must not be doing more than 150 minutes of moderate exercise weekly and should have access to digital devices for intervention tracking.
What is being tested?
The study tests if taking short breaks to move around can help control blood sugar levels in people with type 2 diabetes. It's a randomized crossover trial using continuous glucose monitoring to compare periods with and without movement breaks.
What are the potential side effects?
Since the intervention involves low-intensity movement, side effects might include mild discomfort or muscle soreness similar to starting any new physical activity.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 30 and 75 years old.
Select...
I have been diagnosed with type 2 diabetes by a doctor.
Select...
My medication and its dosage have been stable for the last 6 months.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently taking insulin.
Select...
I am currently taking beta-blockers.
Select...
I am on 3 or more medications for heart disease prevention.
Select...
I have a long-term muscle or bone condition that stops me from exercising.
Select...
I experience chest pain when I exert myself.
Select...
I have a heart or lung condition that stops me from exercising.
Select...
I have conditions like diabetic ulcers or neuropathy that stop me from exercising.
Select...
I am currently receiving dialysis.
Select...
I am taking four or more medications to lower my blood sugar.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48-hour ex trial versus the 48-hour con trial
This trial's timeline: 3 weeks for screening, Varies for treatment, and 48-hour ex trial versus the 48-hour con trial for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean 24-h glucose concentration assessed using continuous glucose monitoring assessed using continuous glucose monitoring
Secondary study objectives
Glycemic variability determined using continuous glucose monitoring
Time above range determined using continuous glucose monitoring
Time below range determined using continuous glucose monitoring
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Exercise (EX): Low-intensity movement breaks conditionExperimental Treatment1 Intervention
Stretching and mobility-based exercises lasting 1-minute each performed 4 times per day on two consecutive days.
Group II: Control (CON) Non-exercise control conditionActive Control1 Intervention
No structured exercise on two consecutive days.

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,481 Previous Clinical Trials
2,494,886 Total Patients Enrolled
McMaster UniversityOTHER
918 Previous Clinical Trials
2,616,263 Total Patients Enrolled
Jonathan Little, PhDPrincipal InvestigatorUniversity of British Columbia
6 Previous Clinical Trials
315 Total Patients Enrolled
~11 spots leftby Jul 2025